Literature DB >> 17221173

Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.

Magdalena Jankowska1, Barbara Butto, Alicja Debska-Slizień, Bolesław Rutkowski.   

Abstract

We report a case of idiopathic inflammatory myopathy accompanied with the presence of anti-Jo1 antibodies and complicated by diffuse parenchymal lung disease (antisynthetase syndrome). Efficacy of different therapeutic agents, including corticosteroids, cyclophosphamide and cyclosporin A, is described. We present beneficial effect of cyclosporin A and corticosteroids regimen, and confirm no benefits of plasmapheresis. An interesting association of the disease onset with toxoplasmosis infection is discussed and difficulties regarding diagnosis of cardiac involvement are addressed. We also review other case reports of this rare disorder of poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17221173     DOI: 10.1007/s00296-006-0289-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  35 in total

Review 1.  Current approach to the treatment of polymyositis and dermatomyositis.

Authors:  C V Oddis
Journal:  Curr Opin Rheumatol       Date:  2000-11       Impact factor: 5.006

2.  Dermatomyositis: practical aspects.

Authors:  Joseph L Jorizzo
Journal:  Arch Dermatol       Date:  2002-01

3.  Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody.

Authors:  M Tomsic; F Sifrer
Journal:  Wien Klin Wochenschr       Date:  2000-08-25       Impact factor: 1.704

4.  Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies--an interesting association.

Authors:  M Kalenian; B Zweiman
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

5.  Fulminant myocarditis in polymyositis.

Authors:  K Yukiiri; K Mizushige; T Ueda; T Nanba; K Tanimoto; Y Wada; Y Takagi; K Ohmori; M Kohno
Journal:  Jpn Circ J       Date:  2001-11

Review 6.  Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.

Authors:  K A Qushmaq; A Chalmers; J M Esdaile
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

7.  Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis.

Authors:  T Yoshida; H Koga; F Saitoh; M Sakamoto; M Harada; H Yoshida; S Sakisaka; M Sata
Journal:  Intern Med       Date:  1999-09       Impact factor: 1.271

8.  Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients.

Authors:  M Akira; H Hara; M Sakatani
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

9.  Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A.

Authors:  Yasuhiro Shimojima; Wataru Ishii; Takashi Kato; Kenichi Hoshi; Masayuki Matsuda; Takao Hashimoto; Yukio Tanaka; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2003-12       Impact factor: 1.271

10.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15
View more
  5 in total

Review 1.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

Review 2.  Antisynthetase syndrome.

Authors:  Elena Katzap; Maria-Louise Barilla-LaBarca; Galina Marder
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 3.  Antisynthetase antibody syndrome: case report and review of the literature.

Authors:  Laura Uribe; Diana Maria Ronderos; Maria Claudia Díaz; Juan Martín Gutierrez; Christina Mallarino; Daniel Gerardo Fernandez-Avila
Journal:  Clin Rheumatol       Date:  2013-02-20       Impact factor: 2.980

4.  Rituximab in life threatening antisynthetase syndrome.

Authors:  E Vandenbroucke; J C Grutters; J Altenburg; W G Boersma; E J ter Borg; J M M van den Bosch
Journal:  Rheumatol Int       Date:  2009-02-01       Impact factor: 2.631

5.  Brief report: antisynthetase syndrome-associated myocarditis.

Authors:  Kavita Sharma; Ana-Maria Orbai; Dipan Desai; Oscar H Cingolani; Marc K Halushka; Lisa Christopher-Stine; Andrew L Mammen; Katherine C Wu; Sammy Zakaria
Journal:  J Card Fail       Date:  2014-07-29       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.